Explore our recent stories to see what drives us
Completion of Joint Venture with Kyowa Kirin International
“With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
As part of this Joint Venture a new standalone company has been created to market KKI’s established medicines portfolio. This company will be branded as Grünenthal Meds. Grünenthal is the majority shareholder of Grünenthal Meds and intends to acquire the remaining shares at the beginning of 2026.